Use of gamma-linolenic acid in the treatment of schizophrenia and tardive dyskinesia
- 31 May 1992
- journal article
- clinical trial
- Published by Elsevier in Prostaglandins, Leukotrienes & Essential Fatty Acids
- Vol. 46 (1) , 67-70
- https://doi.org/10.1016/0952-3278(92)90062-n
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Essential fatty acids in plasma phospholipids in schizophrenicsBiological Psychiatry, 1989
- Fat consumption and schizophreniaActa Psychiatrica Scandinavica, 1988
- Prostaglandin inhibition of apomorphine-induced circling in micePharmacology Biochemistry and Behavior, 1982
- PROSTAGLANDINS AND SCHIZOPHRENIAThe Lancet, 1980
- SCHIZOPHRENIA: RECONCILIATION OF THE DOPAMINE, PROSTAGLANDIN, AND OPIOID CONCEPTS AND THE ROLE OF THE PINEALThe Lancet, 1979
- Penicillin and essential fatty acid supplementation in schizophreniaProstaglandins and Medicine, 1979
- Prostaglandins and schizophrenia: further discussion of the evidencePsychological Medicine, 1978
- SCHIZOPHRENIA AS A PROSTAGLANDIN DEFICIENCY DISEASEThe Lancet, 1977
- Effect of ADP on PGE1Formation in Blood Platelets from Patients with Depression, Mania and SchizophreniaThe British Journal of Psychiatry, 1975
- Absence of Rheumatoid Arthritis in Schizophrenia*Australian and New Zealand Journal of Medicine, 1974